refluxend 20 mg gastro - resistant tablets
alvogen ipco.s.ar.i. - Езомепразол - 20 mg gastro - resistant tablets
refluxend 40 mg gastro - resistant tablets
alvogen ipco.s.ar.i. - Езомепразол - 40 mg gastro - resistant tablets
viranti 5 % cutaneous stick
alvogen ipco s.ar.l - Ацикловир - 5 % cutaneous stick
excloza 25 mg tablets
alvogen ipco.s.ar. i. - 25 mg tablets
excloza 100 mg tablets
alvogen ipco.s.ar. i. - 100 mg tablets
tialera 12,5 mg film - coated tablets
alvogen ipco s.ar.l - 12,5 mg film - coated tablets
potenza 50 mg chewable tablets
alvogen ipco s.ar.l - 50 mg chewable tablets
potenza 100 mg chewable tablets
alvogen ipco s.ar.l - Силденафил - 100 mg chewable tablets
humira
abbvie deutschland gmbh co. kg - адалимумаб - spondylitis, ankylosing; arthritis, juvenile rheumatoid; uveitis; colitis, ulcerative; psoriasis; arthritis, psoriatic; crohn disease; arthritis, rheumatoid - Имуносупресори - Моля, вижте документа с информация за продукта.
pylclari
curium pet france - piflufolastat (18f) - Простатни неоплазми - Диагностични радиофармацевтици - Този лекарствен продукт е само за диагностична употреба. pylclari is indicated for the detection of prostate-specific membrane antigen (psma) positive lesions with positron emission tomography (pet) in adults with prostate cancer (pca) in the following clinical settings:primary staging of patients with high-risk pca prior to initial curative therapy,to localize recurrence of pca in patients with a suspected recurrence based on increasing serum prostate-specific antigen (psa) levels after primary treatment with curative intent. pylclari is indicated for use with positron emission tomography (pet).